# A Safety and Efficacy Study of Eltrombopag in Subjects With AML

Source: https://onco.cc/trials/nct01890746/  
OnCo record `nct01890746` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Daunorubicin, Cytarabine and Eltrombopag in Leukaemia, run by Novartis Pharmaceuticals, completed.

## Summary

A Safety and Efficacy Study of Eltrombopag in Subjects With AML is a phase 2 interventional study registered as NCT01890746 by Novartis Pharmaceuticals, with 148 participants recorded, started 2013-09-05 and reaching its primary completion in 2015-03-13. Interventions recorded: Daunorubicin, Cytarabine, Eltrombopag, Placebo. Conditions recorded: Acute Leukaemia.

Linked to the drug Eltrombopag because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01890746
- Phase: 2
- Setting: A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects With Acute Myelogenous Leukaemia (AML) Receiving Induction Chemotherapy
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 148

## Sources

- ClinicalTrials.gov NCT01890746: https://clinicaltrials.gov/study/NCT01890746

## Connected records

- cancers: [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/)
- drugs: [Cytarabine](https://onco.cc/drugs/cytarabine/), [Daunorubicin](https://onco.cc/drugs/daunorubicin/), [Eltrombopag](https://onco.cc/drugs/eltrombopag/)

---
JSON: https://onco.cc/api/v1/entities/nct01890746.json